Related Experiment Video
Updated: Jul 18, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Innovative insulins--where do analogues fit?
Liza K Phillips1, Patrick J Phillips
1Royal Adelaide Hospital, South Australia.
Australian Family Physician
|December 7, 2006
Summary
Analogue insulins offer improved flexibility and reduced nocturnal hypoglycemia compared to traditional insulins. However, evidence for better glycemic control and long-term outcomes with these advanced insulin formulations remains limited.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Traditional insulins present challenges like delayed action and unpredictable overnight effects.
- Analogue insulins aim to mimic natural insulin secretion for enhanced diabetes management.
- These newer insulins are designed to improve glycemic control without increasing hypoglycemia risk.
Purpose of the Study:
- To review analogue insulins and their current applications in diabetes care.
- To evaluate the advantages and limitations of analogue insulins versus traditional options.
Main Methods:
- Literature review and discussion of clinical evidence for analogue insulins.
- Analysis of pharmacokinetic and clinical data for rapid-acting and basal insulin analogues.
Main Results:
- Bolus and basal analogue insulins provide greater flexibility in diabetes management.
- Basal analogues demonstrate a reduction in nocturnal hypoglycemia episodes.
- Limited evidence currently supports superior glycemic control with analogue insulins compared to traditional ones.
Conclusions:
- Analogue insulins offer benefits such as flexibility and reduced nocturnal hypoglycemia.
- Further research is needed to establish long-term outcomes and definitive glycemic control improvements.
- Specific patient populations, like those with type 1 diabetes and hypoglycemia unawareness, may benefit most from basal analogues.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...